Vildagliptin-LAF237-DataSheet-生命科學試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEVildagliptinCat. No.: HY-14291CAS No.: 274901-16-5Synonyms: LAF237; NVP-LAF 237分式: CHNO分量: 303.4作靶點: Dipeptidyl Peptidase作通路: Metabolic Enzyme/Protease儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數據體外

2、實驗 H2O : 50 mg/mL (164.80 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 3.2960 mL 16.4799 mL 32.9598 mL5 mM 0.6592 mL 3.2960 mL 6.5920 mL10 mM 0.3296 mL 1.6480 mL 3.2960 mL請根據產品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。體內實驗 Vildagliptin is added to drinking water at a concentra

3、tion of 150 mg/L for rats or 300 mg/L for mice4.BIOLOGICAL ACTIVITY物活性 Vildagliptin (LAF-237; NVP-LAF 237)能抑制DPP-4，IC50為2.3 nM。戶使本產品發(fā)表的科研獻1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE Cancer Lett. 2018 Apr 28;420:26-37. bioRxiv. Feb. 7, 2018.See more customer validations on HYPERLINK / www.MedCh

4、emEREFERENCES1. Villhauer EB, Brinkman JA, Naderi GB et al. 1-(3-hydroxy-1-adamantyl) aminoacetyl-2-cyano-(S)-pyrrolidine: a potent, selective, andorally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003;46:2774-89.2. He YL, Kulmatycki K, Zhang Y, Phar

5、macokinetics of vildagliptin in patients with varying degrees of renal impairment. Int J ClinPharmacol Ther. 2013 Jun 19.3. Avila Dde L, Arajo GR, Silva M, Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats.Arch Med Res. 2013 Apr;44(3):194-202.4. Qin CJ, et al. Inhibition of dipeptidyl peptidase IV prevents high fat diet-induced liver cancer angiogenesis by downregulating chemokineligand 2. Cancer Lett. 2018 Jan 31;420:26-37.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-